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Introduction
•

•

•

Group B Streptococcus (GBS) is a
bacterium present in the vaginal
and/or anorectal flora of women
and is considered to be normal
flora which generally does not
cause infection; however, if a
pregnant woman is GBS positive
and left untreated during birth,
the newborn passing through
the birth canal is at risk for
becoming colonized (Bicheno &
Geraghty, 2015, p. 224).

Up to 30% of pregnant women
carry GBS bacteria in their lower
gastrointestinal or genitourinary
tract and up to 1% of neonates
born to colonized mothers
become infected in utero or
during delivery (Fabbrini et al.,
2018).

•

•

Neonates
•
Neonates exposed to GBS, “may
develop symptoms of rapidly
invasive disease including sepsis,
pneumonia, and meningitis within
the first week after birth (earlyonset disease) or after a week and
up to three months of life (lateonset disease)” (Kawa, 2017, p. 20).
•

Maternal Risk Factors
that Increase Chance
of Transmitting GBS to
Infant:

GBS is the “leading infectious
cause of neonatal morbidity and
mortality in the United States”
(Colicchia, Lauderdale, Du,
Adams, & Hirsch, 2015, p. 173).

Diagnosis
•

Signs and Symptoms
Maternal
•
“Women who colonize GBS may be
asymptomatic in pregnancy. It is
possible, however, for women to
become unwell in the postnatal
period. Infections caused by GBS
colonization can include urinary tract
infections, endometritis, wound
infections, puerperal sepsis,
meningitis, and septic
thrombophlebitis” (Bicheno &
Geraghty, 2015, p. 225).

•
•
•
•
•
•
•

Labor or rupture of membranes
before 37 weeks gestation
Membrane rupture more than 18
hours before birth
Urinary tract infection with GBS
during pregnancy
Previous baby with GBS infection
Fever during labor
Chorioamnionitis
Positive culture for GBS colonization
at 35-37 weeks
(CDC, 2018)

•

•

Infants can become ill with earlyonset GBS disease from either
aspirating or ingesting of GBS
positive amniotic fluid during birth,
which could “cause the neonate to
experience a variety of signs and
symptoms, which include low
temperature, pyrexia, bradypnea,
tachypnea, bradycardia,
tachycardia, appear floppy, have
the inability to feed, and appear
pale or irritable” (Bicheno &
Geraghty, 2015, p. 225).

Underlying Pathophysiology
•

•

The process of neonatal infection by GBS is complex and multifactorial. “Host
factors play a central role in determining the pathogenic potential of GBS, but
bacterial virulence factors also assist GBS in the pathogenesis within the host”
(Melin, 2011, p. 1296).
“The first stage in the pathogenesis of GBS is the establishment of vaginal
colonization in the pregnant woman including adherence to vaginal epithelial
cells and resistance to mucosal immune defenses. To gain access to the fetus,
GBS may ascend into the amniotic cavity. Bacterial proliferation allows GBS to
colonize the skin or mucous membranes of the fetus or to enter the fetal lung
through aspiration of infected amniotic fluid. After birth, GBS must successfully
replicate within the alveoli of the neonate, adhere to respiratory epithelium and
avoid clearance by pulmonary macrophages. Pneumonia with lung cell injury is
characteristic of GBS and may be mediated in part by the cytotoxic properties of
GBS…and the influx of host neutrophils. The invasion by GBS of the pulmonary
epithelial and endothelial cells may allow GBS to enter the bloodstream causing
septicemia. This blood stream dissemination may lead to meningitis and
osteomyelitis. This disease progression indicates that GBS has to evade the
host’s natural immune defenses to adhere, to invade, and to transcytose several
cell barriers” (Melin, 2011, p. 1296-1297).

Early-onset GBS disease occurs
more often and is more fatal than
late-onset GBS disease (Sheehy,
Davis, & Homer, 2013).

•
•

•

Infected infants who survive may
experience life-long impairments,
such as deafness, blindness, or
developmental issues (CDC, 2018).

If a woman who is pregnant tests
positive for GBS, it is recommended
that she is treated with penicillin G
at least four hours before delivery
(with at least two doses) for
maximum effectiveness. If a mom is
allergic to penicillin G, with a low
concern for an anaphylaxis reaction,
then cefazolin is recommended. If
there is a risk for an anaphylactic
reaction, then clindamycin is the
next option with vancomycin also
being available if a mom’s culture
indicates resistance to clindamycin
(Apgar et al., 2005, p. 903).
If a woman tests negative for GBS,
then no antibiotic or treatment is
necessary.
If a pregnant carrier of GBS receives
IV antibiotics during delivery, her
baby has a 1 in 4,000 chance of
developing GBS infection. Without
antibiotics, her baby has a 1 in 200
chance of developing GBS infection
(CDC, 2018).
The antibiotics used to prevent
early-onset group B strep disease in
newborns only help during
labor. Pregnant women cannot take
them before labor, because the
bacteria can grow back quickly (CDC,
2018).

Implications for
Nursing Care

GBS samples are collected using a
single swab technique, where the
vagina is swabbed first, followed
by the rectum (Sheehy et al.,
2013). The GBS cultures take 24 to
48 hours to result and the results
are considered valid for five weeks
(Bicheno & Geraghty, 2015).

•

A neonate may be tested and
diagnosed with GBS from either a
blood test, urine specimen, or by
cerebrospinal fluid (Bicheno &
Geraghty, 2015, p. 225).

Figure 2. Recommended intrapartum antibiotic regimen
(Verani, McGee, & Schrag, 2010)

Significance of Pathophysiology

GBS status can be variable
between pregnancies and even
transient during a given
pregnancy, so the mother must be
tested each pregnancy (Colicchia
et al., 2015).
Figure 1. Incidence of early-onset and late-onset invasive GBS
disease and activities of prevention of GBS disease (Verani, McGee,
& Schrag, 2010).

GBS is an encapsulated gram-positive diplococcus frequently found in the human
gastrointestinal or lower genital tract (Cho, et al., 2017). The significance of GBS can be
devastating on an infant if not correctly detected or treated on a GBS positive mother as
GBS is the leading cause of neonatal sepsis and meningitis, which could lead to death
(Melin, 2011). GBS can also cause invasive bacterial infections and pneumonia during the
first week of life (Melin, 2011). Infants that survive GBS meningitis have a 50% chance of
having long-term impairments and up to 30% have severe neurological deficits (Melin,
2011). Per Melin (2011), about 30-70% of neonates born to GBS positive mothers become
transiently colonized by their mother’s organism. Most of them remain asymptomatic, but
among these infants 1-3% develop a severe disease from the GBS (Melin, 2011, p. 1295).
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Health care providers need to be
vigilant about screening for GBS in
pregnancy. All women who are
pregnant should be tested for GBS
at 35 to 37 weeks’ gestation in each
pregnancy (Zolotor & Carlough,
2014).
Individuals who have a history of
preterm labor or exhibit signs of
preterm labor, may need to be
tested sooner or every five weeks
for GBS.
When caring for a neonate, the
health care provider should review
maternal testing to ensure that the
GBS result for the mother was
obtained and she was treated
during labor.
GBBS positive may be spread from
infant to infant if precise
handwashing technique is not used
when handling newborns
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Conclusion
In conclusion, GBS screening and
treatment will ‘facilitate early
detection and antibiotic treatment
that will decrease the probability of
neonatal infection, thereby reducing
damage, regrets, and medical
expenditure” (Hung et al., 2018, p. 2).
All women should be screened for
GBS at prenatal appointments since a
GBS vaccine is not yet available
(Fabbrini et al., 2018). By screening
women at prenatal appointments for
GBS, it could help prevent infants
from contracting early-onset GBS or
late-onset GBS disease and possibly
preventing the infants from death or
life-long disabilities. Antibiotic
administration during labor to
pregnant women colonized with GBS
can help prevent the transmission of
GBS infection, and thus decrease the
incidence of early and late onset GBS
disease in newborns.

Cho, C. Y., Tang, Y. H., Chen, Y. H., Wang, S. Y., Yang, Y. H.,
Wang, T. H., … Jeng, M. J. (2017). Group B streptococcal
infection in neonates and colonization in pregnant
women: An epidemiological retrospective analysis. Journal
of Microbiology, Immunology and Infection. 1-8. doi:
10.1016/ j.jmii.2017.08.004
Colicchia, L. C., Lauderdale, D. S., Du, H., Adams, M., &
Hirsch, E. (2015). Recurrence of group B streptococcus
colonization in successive pregnancies. Journal of
Perinatology, 35(3), 173-176. doi:10.1038/jp.2014.185
Fabbrini, M., Rigat, F., Tuscano, G., Chiarot, E., Donders,
G., Devlieger, R., ...Margarit, I. (2018). Functional activity
of maternal and cord antibodies elicited by an
investigational group B streptococcus trivalent
glycoconjugate vaccine in pregnant women. Journal of
Infection, 76(5), 449-456. doi:10.1016/j.jinf.2018.01.006
Hung, L., Kung, P., Chiu, T., Su, H., Ho, M., Kao, H., ...Tsai,
W. (2018). Risk factors for neonatal early-onset group B
streptococcus-related diseases after the implementation
of a universal screening program in Taiwan. BMC Public
Health, 18(1), 1-9. doi:10.1186/s12889-018-5358-0
Kawa, D. (2017). Detection methods for prevention of
early-onset neonatal group B strep infections. Medical
Laboratory Observer, 49(5), 20-21.
Melin, P. (2011). Neonatal group B streptococcal disease:
from pathogenesis to preventive strategies. Clinical
Microbiology and Infection,17(9), 1294-1303.
doi:10.1111/j.1469-0691.2011.03576.x
Sheehy, A., Davis, D., & Homer, C. S. (2013). Assisting
women to make informed choices about screening for
group B streptococcus in pregnancy: A critical review of
the evidence. Women and Birth, 26(2), 152-157.
doi:10.1016/j.wombi.2012.10.004
Verani, J. R., McGee, L., & Schrag, S. J. (2010). Prevention
of perinatal group B streptococcal disease. Morbidity and
Mortality Weekly Report, 59(10), 1-32. Retrieved from
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5910
a1.htm
Zolotor, A. J., & Carlough, M. C. (2014). Update on
prenatal care. American Family Physician, 89(3), 199-208.

Retrieved from Verani, McGee, &
Schrag (2010)

